Chronic exposure to MDMA (Ecstasy) elicits behavioral sensitization in rats but fails to induce cross-sensitization to other psychostimulants

Behavioral and Brain Functions

Volumn 2, Issue , 2006, Pages

  Modi, Gunjan M ^a   Yang, Pamela B ^a   Swann, Alan C ^a   Dafny, Nachum ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; METHYLPHENIDATE; PSYCHOSTIMULANT AGENT; SODIUM CHLORIDE;

ACUTE DRUG ADMINISTRATION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOMATION; COMPUTER SYSTEM; CONTROLLED STUDY; DRUG SENSITIZATION; LONG TERM EXPOSURE; MALE; MONITORING; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZATION; RAT; RAT STRAIN; RECORDING; STATISTICAL SIGNIFICANCE;

EID: 33646419564     PISSN: 17449081     EISSN: None     Source Type: Journal    
DOI: 10.1186/1744-9081-2-1     Document Type: Article

References (69)

1. Strote J, Lee JE, Wechsler H: Increasing MDMA use among college students: results of a national survey. J Adolesc Health 2002, 30(1):64-72.
2. Johnston LD, O'Malley PM, Bachman JG: Monitoring the Future national results on adolescent drug use: Overview of key findings, 2002. National Institutes on Drug Abuse 2003, NIH Publication No. 03-5374:.
3. Landry MJ: MDMA: a review of epidemiologic data. J Psychoactive Drugs 2002, 34(2):163-169.
4. Broening HW, Morford LL, Inman-Wood SL, Fukumura M, Vorhees CV: 3,4-methylenedioxymethamphetamine (ecstasy)-induced learning and memory impairments depend on the age of exposure during early development. J Neurosci 2001, 21(9):3228-3235.
5. Williams MT, Morford LL, Wood SL, Rock SL, McCrea AE, Fukumura M, Wallace TL, Broening HW, Moran MS, Vorhees CV: Developmental 3,4-methylenedioxymethamphetamine (MDMA) impairs sequential and spatial but not cued learning independent of growth, litter effects or injection stress. Brain Res 2003, 968(1):89-101.
6. Morley KC, Gallate JE, Hunt GE, Mallet PE, McGregor IS: Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine ("ecstasy"). Eur J Pharmacol 2001, 433(1):91-99.
7. Sprague JE, Preston AS, Leifheit M, Woodside B: Hippocampal serotonergic damage induced by MDMA (ecstasy): effects on spatial learning. Physiol Behav 2003, 79(2):281-287.
8. Marston HM, Reid ME, Lawrence JA, Olverman HJ, Butcher SP: Behavioural analysis of the acute and chronic effects of MDMA treatment in the rat. Psychopharmacology (Berl) 1999, 144(1):67-76.
9. Fone KC, Beckett SR, Topham IA, Swettenham J, Ball M, Maddocks L: Long-term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity. Psychopharmacology (Berl) 2002, 159(4):437-444.
10. Gurtman CG, Morley KC, Li KM, Hunt GE, McGregor IS: Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonin depletion. Eur J Pharmacol 2002, 446(1-3):89-96.
11. Maldonado E, Navarro JF: MDMA ("ecstasy") exhibits an anxiogenic-like activity in social encounters between male mice. Pharmacol Res 2001, 44(1):27-31.
12. Matuszewich L, Filon ME, Finn DA, Yamamoto BK: Altered forebrain neurotransmitter responses to immobilization stress following 3,4-methylenedioxymethamphetamine. Neuroscience 2002, 110(1):41-48.
13. Kalant H: The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. Cmaj 2001, 165(7):917-928.
14. Spanos LJ, Yamamoto BK: Acute and subchronic effects of methylenedioxymethamphetamine [(+/-)MDMA] on locomotion and serotonin syndrome behavior in the rat. Pharmacol Biochem Behav 1989, 32(4):835-840.
15. Gold LH, Koob GF: MDMA produces stimulant-like conditioned locomotor activity. Psychopharmacology (Berl) 1989, 99(3):352-356.
16. McNamara MG, Kelly JP, Leonard BE: Some behavioural and neurochemical aspects of subacute (+/-)3,4-methylenedioxymethamphetamine administration in rats. Pharmacol Biochem Behav 1995, 52(3):479-484.
17. Dar KJ, McBrien ME: MDMA induced hyperthermia: report of a fatality and review of current therapy. Intensive Care Med 1996, 22(9):995-996.
18. Dafters RI: Hyperthermia following MDMA administration in rats: effects of ambient temperature, water consumption, and chronic dosing. Physiol Behav 1995, 58(5):877-882.
19. Gowing LR, Henry-Edwards SM, Irvine RJ, Ali RL: The health effects of ecstasy: a literature review. Drug Alcohol Rev 2002, 21(1):53-63.
20. Gordon CJ, Watkinson WP, O'Callaghan JP, Miller DB: Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat. Pharmacol Biochem Behav 1991, 38(2):339-344.
21. Traub SJ, Hoffman RS, Nelson LS: The "ecstasy" hangover: hyponatremia due to 3,4-methylenedioxymethamphetamine. J Urban Health 2002, 79(4):549-555.
22. Gudelsky GA, Nash JF: Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem 1996, 66(1):243-249.
23. Marona-Lewicka D, Rhee GS, Sprague JE, Nichols DE: Reinforcing effects of certain serotonin-releasing amphetamine derivatives. Pharmacol Biochem Behav 1996, 53(1):99-105.
24. Shankaran M, Yamamoto BK, Gudelsky GA: Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine. Eur J Pharmacol 1999, 385(2-3):103-110.
25. Robinson TE, Berridge KC: The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 1993, 18(3):247-291.
26. Robinson TE, Becker JB: Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 1986, 396(2):157-198.
27. Kalivas PW, Duffy P, White SR: MDMA elicits behavioral and neurochemical sensitization in rats. Neuropsychopharmacology 1998, 18(6):469-479.
28. Gaytan O, Swann AC, Dafny N: Effects of amphetamine at the beginning of the light cycle on multiple indices of motor activity in the rat. Eur J Pharmacol 1996, 300(1-2):1-8.
29. Gaytan O, al-Rahim S, Swann A, Dafny N: Sensitization to locomotor effects of methylphenidate in the rat. Life Sci 1997, 61(8):PL101-7.
30. Yang P, Singhal N, Modi G, Swann A, Dafny N: Effects of lithium chloride on induction and expression of methylphenidate sensitization. Eur J Pharmacol 2001, 426(1-2):65-72.
31. Nagilla R, Newland MC, Snyder J, Bronson ME: Effect of once weekly treatment with 3,4-methylenedioxymethamphetamine on schedule-controlled behavior in rats. Eur J Pharmacol 1998, 358(1):1-8.
32. Callaway CW, Geyer MA: Tolerance and cross-tolerance to the activating effects of 3,4-methylenedioxymethamphetamine and a 5-hydroxytryptamineIB agonist. J Pharmacol Exp Ther 1992, 263(1):318-326.
33. Bonate PL, Swann A, Silverman PB: Context-dependent cross-sensitization between cocaine and amphetamine. Life Sci 1997, 60(1):PL1-7.
34. Yang PB, Swann AC, Dafny N: Chronic pretreatment with methylphenidate induces cross-sensitization with amphetamine. Life Sci 2003, 73(22):2899-2911.
35. Brandon CL, Marinelli M, Baker LK, White FJ: Enhanced reactivity and vulnerability to cocaine following methylphenidate treatment in adolescent rats. Neuropsychopharmacology 2001, 25(5):651-661.
36. Itzhak Y, Ali SF, Achat CN, Anderson KL: Relevance of MDMA ("ecstasy")-induced neurotoxicity to long-lasting psychomotor stimulation in mice. Psychopharmacology (Berl) 2003, 166(3):241-248.
37. Achat-Mendes C, Anderson KL, Itzhak Y: Methylphenidate and MDMA adolescent exposure in mice: long-lasting consequences on cocaine-induced reward and psychomotor stimulation in adulthood. Neuropharmacology 2003, 45(1):106-115.
38. Segal DS, Geyer MA, Schuckit MA: Stimulant-induced psychosis: an evaluation of animal methods. Essays Neurochem Neuropharmacol 1981, 5:95-129.
39. Fletcher PJ, Robinson SR, Slippoy DL: Pre-exposure to (+/ -)3,4-methylenedioxy-methamphetamine (MDMA) facilitates acquisition of intravenous cocaine self-administration in rats. Neuropsychopharmocology 2001, 25(2):195-203.
40. Bjork JM, Gaytan O, Patt N, Swann AC, Dafny N: Behavioral tolerance to and withdrawal from multiple fluoxetine administration. Int J Neurosci 1998, 93(3-4):163-179.
41. Cole JC, Sumnall HR: The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci Biobehav Rev 2003, 27(3):199-217.
42. Ratzenboeck E, Saria A, Kriechbaum N, Zernig G: Reinforcing effects of MDMA ("ecstasy") in drug-naive and cocaine-trained rats. Pharmacology 2001, 62(3):138-144.
43. Schenk S, Gittings D, Johnstone M, Daniela E: Development, maintenance and temporal pattern of self-administration maintained by ecstasy (MDMA) in rats. Psychopharmacology (Berl) 2003, 169(1):21-27.
44. Cornish JL, Shahnawaz Z, Thompson MR, Wong S, Morley KC, Hunt GE, McGregor IS: Heat increases 3,4-methylenedioxymethamphetamine self-administration and social effects in rats. Eur J Pharmacol 2003, 482(1-3):339-341.
45. Fletcher PJ, Korth KM, Robinson SR, Baker GB: Multiple 5-HT receptors are involved in the effects of acute MDMA treatment: studies on locomotor activity and responding for conditioned reinforcement. Psychopharmacology (Berl) 2002, 162(3):282-291.
46. Anderson KL, Itzhak Y: Inhibition of neuronal nitric oxide synthase suppresses the maintenance but not the induction of psychomotor sensitization to MDMA ('Ecstasy') and p-chloroamphetamine in mice. Nitric Oxide 2003, 9(1):24-32.
47. McCreary AC, Bankson MG, Cunningham KA: Pharmacological studies of the acute and chronic effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine (IA) and 5-hydroxytryptamine(IB/ID) receptors. J Pharmacol Exp Ther 1999, 290(3):965-973.
48. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI: The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MIDMA, "ecstasy"). Pharmacol Rev 2003, 55(3):463-508.
49. Pierce RC, Kalivas PW: A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Brain Res Rev 1997, 25(2):192-216.
50. Kalivas PW, Duffy P: Time course of extracellular dopamine and behavioral sensitization to cocaine. I. Dopamine axon terminals. J Neurosci 1993, 13(1):266-275.
51. Callaway CW, Wing LL, Geyer MA: Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther 1990, 254(2):456-464.
52. Gold LH, Koob GF, Geyer MA: Stimulant and hallucinogenic behavioral profiles of 3,4-methylenedioxymethamphetamine and N-ethyl-3,4-methylenedioxyamphetamine in rats. J Pharmacol Exp Ther 1988, 247(2):547-555.
53. Gough B, Ali SF, Slikker WJ, Holson RR: Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate. Pharmacol Biochem Behav 1991, 39(3):619-623.
54. Yamamoto BK, Spanos LJ: The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur J Pharmacol 1988, 148(2):195-203.
55. Colado MI, Camarero J, Mechan AO, Sanchez V, Esteban B, Elliott JM, Green AR: A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on dopamine neurones in mouse brain. Br J Pharmacol 2001, 134(8):1711-1723.
56. O'Shea E, Esteban B, Camarero J, Green AR, Colado MI: Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ('ecstasy') on the 5-HT and dopamine concentrations in mouse brain. Neuropharmacology 2001, 40(1):65-74.
57. Koch S, Galloway MP: MDMA induced dopamine release in vivo: role of endogenous serotonin. J Neural Transm 1997, 104(2-3):135-146.
58. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG: Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996, 379(6566):606-612.
59. Karler R, Calder LD, Thai LH, Bedingfield JB: The dopaminergic, glutamatergic, GABAergic bases for the action of amphetamine and cocaine. Brain Res 1995, 671(1):100-104.
60. Pettit HO, Pan HT, Parsons LH, Justice JBJ: Extracellular concentrations of cocaine and dopamine are enhanced during chronic cocaine administration. J Neurochem 1990, 55(3):798-804.
61. Paulson PE, Robinson TE: Amphetamine-induced time-dependent sensitization of dopamine neurotransmission in the dorsal and ventral striatum: a microdialysis study in behaving rats. Synapse 1995, 19(1):56-65.
62. Paulson PE, Camp DM, Robinson TE: Time course of transient behavioral depression and persistent behavioral sensitization in relation to regional brain monoamine concentrations during amphetamine withdrawal in rats. Psychopharmacology (Berl) 1991, 103(4):480-492.
63. Wise RA, Leeb K: Psychomotor-stimulant sensitization: a unitary phenomenon? Behav Pharmacol 1993, 4(4):339-349.
64. Cole JC, Sumnall HR, O'Shea E, Marsden CA: Effects of MDMA exposure on the conditioned place preference produced by other drugs of abuse. Psychopharmacology (Berl) 2003, 166(4):383-390.
65. Horan B, Gardner EL, Ashby CRJ: Enhancement of conditioned place preference response to cocaine in rats following subchronic administration of 3,4-methylenedioxymethamphetamine (MDMA). Synapse 2000, 35(2):160-162.
66. Morgan AE, Horan B, Dewey SL, Ashby CRJ: Repeated administration of 3,4-methylenedioxymethamphetamine augments cocaine's action on dopamine in the nucleus accumbens: a microdialysis study. Eur J Pharmacol 1997, 331(1):R1-3.
67. Yamamoto BK, Nash JF, Gudelsky GA: Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J Pharmacol Exp Ther 1995, 273(3):1063-1070.
68. Gaytan O, Yang P, Swann A, Dafny N: Diurnal differences in sensitization to methylphenidate. Brain Res 2000, 864(1):24-39.
69. Gaytan O, Swann A, Dafny N: Time-dependent differences in the rat's motor response to amphetamine. Pharmacol Biochem Behav 1998, 59(2):459-467.